

1 **Global Profiling of the Lysine Crotonylome in Different** 2 **Pluripotent States**

3 Yuan Lv^{1,2,3,#}, Chen Bu^{4,#}, Jin Meng^{1,2,5}, Carl Ward^{1,2}, Giacomo Volpe^{1,2}, Jieyi Hu^{1,2,3},
4 Mengling Jiang^{1,2}, Lin Guo², Jiekai Chen^{2,3,5,6}, Miguel A. Esteban^{1,2,5,6,7,*}, Xichen
5 Bao^{2,6,8*}, Zhongyi Cheng^{4,*}

6 ¹ *Laboratory of Integrative Biology, Guangzhou Institutes of Biomedicine and Health,*
7 *Chinese Academy of Sciences, Guangzhou 510530, China*

8 ² *Key Laboratory of Regenerative Biology and Guangdong Provincial Key Laboratory*
9 *of Stem Cells and Regenerative Medicine, Guangzhou Institutes of Biomedicine and*
10 *Health, Chinese Academy of Sciences, Guangzhou 510530, China*

11 ³ *University of Chinese Academy of Sciences, Beijing 100049, China*

12 ⁴ *Jingjie PTM BioLab (Hangzhou) Co.Ltd, Hangzhou 310018, China*

13 ⁵ *Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health and*
14 *Guangzhou Medical University, Guangzhou 511436, China*

15 ⁶ *Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou*
16 *510005, China*

17 ⁷ *Institute for Stem Cells and Regeneration, Chinese Academy of Sciences, Beijing*
18 *100101, China*

19 ⁸ *Laboratory of RNA Molecular Biology, Guangzhou Institutes of Biomedicine and*
20 *Health, Chinese Academy of Sciences, Guangzhou 510530, China*

21

22 # Co-first authors

23 * Corresponding authors

24 E-mail: zhongyi_cheng@ptm-biolab.com (Cheng Z), bao_xichen@gibh.ac.cn (Bao
25 X), miguel@gibh.ac.cn (Esteban MA).

26

27 **Running title:**

28 *Yuan L et al / Lysine Crotonylome in Pluripotent Cells*

29

30 **ORCID**

31 0000-0003-1260-5800 (Lv Y)

32 0000-0002-1377-6858 (Bu C)

33 0000-0003-1857-2843 (Meng J)

34 0000-0003-0889-9025 (Ward C)

35 0000-0001-5000-6951 (Volpe G)

36 0000-0001-5698-270X (Guo L)

37 0000-0001-6905-3694 (Hu J)

38 0000-0001-7484-6891 (Jiang M)

39 0000-0001-5168-7074 (Chen J)

40 0000-0002-1426-6809 (Esteban MA)

41 0000-0003-0389-4233 (Bao X)

42 0000-0002-8764-2019 (Cheng Z)

43

44 Total counts of **words**: 9331

45 Total counts of **figures**: 4

46 Total counts of **tables**: 1

47 Total counts of **supplementary figures**: 6

48 Total counts of **supplementary tables**: 4

49 Total counts of **references**: 56

50 Total counts of **references since 2014**: 35

51 **Abstract**

52 Pluripotent stem cells (PSCs) can be expanded *in vitro* in different culture conditions,
53 resulting in a spectrum of cell states with distinct properties. Understanding how
54 PSCs transition from one state to another, ultimately leading to lineage-specific
55 differentiation, is important for developmental biology and regenerative medicine.
56 Although there is significant information regarding gene expression changes
57 controlling these transitions, less is known about post-translational modifications of
58 proteins. Protein crotonylation is a newly discovered post-translational modification
59 where lysine residues are modified with a crotonyl group. Here, we employed affinity
60 purification of crotonylated peptides and liquid chromatography-tandem mass
61 spectrometry (LC-MS/MS) to systematically profile protein crotonylation in mouse
62 PSCs in different states including ground, metastable and primed state, as well as
63 metastable PSCs undergoing early pluripotency exit. We successfully identified 3628
64 high-confidence sites in 1426 proteins. These crotonylated proteins are enriched for
65 factors involved in functions related to pluripotency such as RNA biogenesis, central
66 carbon metabolism and proteasome function. Moreover, we found that increasing the
67 cellular levels of crotonyl-CoA through crotonic acid treatment promotes proteasome
68 activity in metastable PSCs and delays their differentiation, consistent with previous
69 observations showing that enhanced proteasomal activity helps to sustain
70 pluripotency. Our atlas of protein crotonylation will be valuable for further studies of
71 pluripotency regulation and may also provide insights into the role of metabolism in
72 other cell fate transitions.

73

74 **KEYWORDS:** Metabolism; Crotonylation; Pluripotency; RNA-binding proteins;
75 Proteasome

76

77 **Introduction**

78 Pluripotency is a transient state of the developing embryo. Through this property,
79 cells in the inner cell mass (ICM) of the blastocyst have the capacity to differentiate
80 into all tissues that compose the body [1]. *In vitro*, pluripotency can be maintained by
81 culturing ICM cells in specific conditions, which then produces PSCs. Accordingly,
82 PSCs are self-renewing, can be maintained indefinitely *in vitro* and differentiated on
83 demand upon exposure to specific signalling cues. Studying the regulation of
84 pluripotency maintenance and exit in PSCs is important not only to understand
85 embryonic development but also for cell fate transitions in other contexts (*e.g.*,
86 somatic cell reprogramming and transdifferentiation, cancer, or aging). Mouse PSCs
87 are a well-studied pluripotency model and can be cultured in different conditions:
88 ground state (in serum-free medium with MEK and GSK3 inhibitors, or 2i embryonic
89 stem cells [ESCs]), metastable state (with serum and leukemia inhibitory factor [LIF],
90 or S/L ESCs), and primed state (in serum-free medium with bFGF and Activin A; or
91 epiblast stem cells [EpiSCs]) [2, 3]. Each of these pluripotent states represents a
92 downwards progression from the early preimplantation blastocyst to the
93 post-implantation embryo. PSCs in 2i more closely resemble the pre-implantation
94 ICM and produce chimeras upon blastocyst complementation more efficiently than
95 metastable PSCs. On the contrary, EpiSCs resemble the post-implantation ICM and
96 have negligible capacity to contribute to chimeras. The term metastable refers to the
97 tendency of S/L ESCs to spontaneously oscillate between more naïve (ICM-like)
98 conditions and the primed state [4]. Notably, cells in these three pluripotent states
99 display differences in their epigenome, transcriptome and metabolome, as their
100 function is controlled by different signalling pathways [5, 6]. Regarding metabolism,
101 naive PSCs rely on both glycolysis and oxidative phosphorylation (through the
102 tricarboxylic, TCA, cycle) for producing energy, whereas EpiSCs mostly rely on
103 glycolysis [6, 7].

104 Besides providing energy, cell metabolism regulates myriad cellular functions
105 comprehensively including modifications in DNA/histones, the transcriptome, and the
106 proteome. Because metabolic features are variable in different cell types, changing
107 metabolism can influence cell fate transitions. For instance, a rapid decrease of
108 glycolysis during mouse ESC differentiation leads to reduced abundance of
109 acetyl-coenzyme A (acetyl-CoA) and a consequent decline in histone lysine
110 acetylation (an epigenetic mark associated with gene activation) at pluripotency loci
111 [8]. Likewise, down regulation of SAM (S-adenosyl-methionine) caused by threonine
112 depletion results in decreased trimethylation of histone H3 lysine 4, which slows PSC
113 proliferation and facilitates differentiation [9]. Recently, a group of novel metabolites
114 derived from short-chain fatty acids (*e.g.*, propionyl-CoA, crotonyl-CoA,
115 butyryl-CoA, and myristoyl-CoA, among others) have been shown to be substrate for
116 lysine acylation of not only histones but also non-histone proteins involved in many
117 cellular processes [10, 11]. These post-translational modifications are functionally
118 relevant and distinct from protein lysine acetylation mediated by acetyl-CoA, further
119 strengthening the link between metabolism and cellular functions beyond energy
120 production. For example, during starvation histone 3 lysine 9 β -hydroxybutyrylation
121 activates responsive genes in the mouse liver to induce adaption [12]. Similarly,
122 lysine myristoylation of germline proteins can modulate the MPK-1/MAPK pathway
123 to impact sex determination and reproductive development in *Caenorhabditis elegans*
124 [13]. Moreover, lysine crotonylation (Kcr) in histones activates gene expression
125 through yet unclear mechanisms, and a large repertoire of non-histone proteins can be
126 crotonylated too [14, 15]. For example, crotonylation of RPA1 promotes homologous
127 recombination-mediated DNA repair by enhancing its interaction with single-strand
128 DNA [16]. Yet, comprehensive analysis of these novel post-translational
129 modifications, including crotonylation, in different cell types and during cell fate
130 transitions is largely lacking.

131 In this report, we have constructed an atlas of Kcr, with focus on non-histone
132 proteins, in different mouse pluripotent states (2i ESCs, S/L ESCs, and EpiSCs) and
133 also S/L ESCs allowed to exit pluripotency by removing LIF. We have identified
134 3628 high-confident Kcr sites on 1426 proteins among these four cell states. These
135 sites reveal links between crotonylation and cell functions relevant for pluripotency
136 maintenance, including RNA biogenesis, carbon metabolism, and the proteasome.
137 Consistently, we observed that increased protein crotonylation caused by crotonic
138 acid administration up-regulates pluripotency gene expression, delays differentiation,
139 and enhances proteasome activity, a function relevant for pluripotency maintenance
140 [17, 18]. Our findings provide a useful resource for understanding how metabolism
141 regulates cell identity through crotonyl-CoA production, in particular the transition
142 between different pluripotent states and differentiated cells.

143

144 **Results and discussion**

145 **Quantitative lysine crotonylome analysis in different pluripotent states and** 146 **differentiated cells**

147 We aimed to investigate protein crotonylation in mouse PSCs in different states: 2i
148 ESCs, S/L ESCs, EpiSCs, and also S/L ESCs triggered to exit pluripotency by LIF
149 withdrawal for 4 days (hereafter referred to as differentiating cells) (**Figure 1A**). To
150 monitor the different PSC states, we used ESCs and EpiSCs derived from crossed
151 offspring of 129 female mice and OG2 transgenic male mice. These cells contain
152 multiple copies of an *Oct4* distal enhancer-driven GFP reporter activated only in naïve
153 pluripotency conditions [19, 20]. ESCs in 2i and S/L showed bright GFP fluorescence
154 as well as the characteristic domed colony shape, whereas EpiSCs and differentiated
155 cells had lost the GFP signal and displayed flat and flat/irregular colony shape,
156 respectively (Figure S1A). To further verify the different cell identities, we performed
157 reverse transcription-quantitative PCR (RT-qPCR) for general pluripotency markers
158 (*Nanog* and *Oct4/Pou5f1*), pluripotent state-specific regulators (*Lin28a* and *Myc*) [21,

159 22] and EpiSC/differentiation markers (*Fgf5*). EpiSCs and differentiating cells
160 showed higher expression of *Fgf5* compared to naïve ESCs (2i or S/L conditions), and
161 2i ESCs showed the lowest expression of *Myc*, *Lin28a*, and *Fgf5*, but the highest
162 expression of *Nanog* and to a lesser extent *Oct4* (Figure S1B). These results
163 demonstrate that our culture conditions truly represent the above-mentioned cell
164 states.

165 Next, we quantified the lysine crotonylome of cells in these four culture
166 conditions. To this end, we labelled the digested peptides from different conditions
167 with tandem mass tags (TMT). We combined and fractionated the labelled peptides
168 with high-performance liquid chromatography, and then enriched them with anti-Kcr
169 antibodies [14] before conducting mass spectrometry analysis. Altogether, we
170 identified 8,102 different sites in 2578 proteins among the four cell types, which were
171 divided into high- (3628 sites in 1426 proteins) or low-confidence (4474 sites in 1152
172 proteins) candidates (Table 1 and S1A). High-confidence proteins were defined as
173 quantified in at least two experiments out of three, and low-confidence as quantified
174 only in one experiment). For example, we detected the chromatin regulator HDAC1
175 (Histone deacetylase 1), a known target of crotonylation [23], among the
176 high-confidence crotonylated proteins (Figure 1B). In addition, we analyzed the total
177 proteome (Table 1). Both the total proteome and the lysine crotonylome showed high
178 reproducibility in three biological replicates (Figure S1C and 1C).

179 We then integrated our total proteome with the publicly available ‘core ESC-like
180 gene module’ and the ‘adult tissue stem module’, which represent pluripotency
181 regulators and differentiation regulators enriched in mouse ESCs and adult stem cells,
182 respectively [24]. As anticipated, the ‘core ESC-like gene module’ scored the lowest
183 in differentiating cells, whereas the ‘adult tissue stem module’ was the lowest in
184 ground state PSCs but the highest in the differentiating cells (Figure S1D).
185 Importantly, principal component analysis (PCA) of our crotonylome and proteome
186 datasets could also distinguish cells in the four cell states (Figure 1D and S1G). The

187 largest Euclidean distances in the crotonylome PCA were between 2i ESCs and the
188 differentiating cells, consistent with the functional divergence between them. These
189 observations support the notion that protein crotonylation may be functionally
190 important for maintaining cell identity in these different culture conditions. In this
191 regard, protein crotonylation is controlled by the balance between writers and erasers
192 [25], whose changes in expression could explain putative differences in crotonylation
193 between the four cell states. However, analysis of the total proteome showed that
194 known crotonylation writers and erasers (also crotonylation readers) do not change
195 noticeably between the four cell states (Figure S1E). Likewise, global crotonylation
196 was at an equivalent level too (Figure S1F).

197 In summary, we have successfully profiled global protein crotonylation in
198 different pluripotent states including 2i ESCs, S/L ESCs, EpiSCs, and also in early
199 differentiating PSCs.

200

201 **Characteristics of the crotonylated proteins in the four cell states**

202 We next studied the features of the 1426 high-confidence crotonylated proteins
203 identified among the four cell states. Of note, 686 proteins showed at least two
204 crotonylated sites, whereas 30 showed more than 12 modification sites (**Figure 2A**
205 and Table S1B). Analysis of the subcellular localization using the
206 COMPARTMENTS database [26] showed that these crotonylated proteins exert
207 different functions in multiple compartments including nucleus, cytoplasm, plasma
208 membrane, cytoskeleton, and mitochondria (Figure 2B and Table S1C). We also
209 compared our complete Kcr dataset with published crotonylomes in different human
210 cells including H1299 [15], HeLa [23], A549 [27], and HCT116 cells [28], and also
211 peripheral blood from patients with kidney failure [29], all of which described
212 identified crotonylated proteins without selection of high-confidence ones. Our
213 dataset was the largest, with 886 out of the total 2578 crotonylated proteins (high- and
214 low-confidence candidates) being unique to it (Figure 2C and Table S1D). To validate

215 the identified candidates, we selected and overexpressed 15 high-confidence proteins
216 and one low-confidence protein with a FLAG tag in HEK293T cells, followed by
217 immunoprecipitation and western blotting with Kcr antibodies. The substrate for
218 crotonyl-CoA generation, crotonic acid, was added to enhance the detection.
219 Importantly, 11 out of 16 candidates showed increased basal Kcr signal, crotonic acid
220 treatment boosted the basal signal in most of the selected candidates (15 out of 16)
221 (Figure 2D and S2). Three out of the 15 validated proteins, including the pluripotency
222 regulator LIN28A and the RNA m⁶A reader YTHDF2 [30], were exclusive to our
223 own dataset. These results support the reliability of our proteomic experiments and
224 analysis.

225

226 **RNA binding proteins are highly represented in the four cell states crotonylome**

227 We then performed gene ontology (GO) and KEGG pathway analysis of the 1426
228 high-confidence crotonylated proteins. Interestingly, GO analysis showed enrichment
229 in RNA metabolism-related and ribosome-related terms (Figure 2E and Table S2A).
230 Consistent with the former functional enrichment analysis, classical RNA binding
231 domains (Figure S3A) and experimentally identified RNA binding proteins (RBPs)
232 from other studies [31-33] (Figure S3B and Table S2B) were enriched in our
233 high-confidence crotonylome dataset. This is perhaps not surprising because lysine is
234 one of the most commonly enriched amino acids in the RNA binding domains of
235 RBPs [34]. Thus, RBP crotonylation may be a widespread mechanism for regulating
236 RNA-protein interactions by neutralizing the positive charge on lysine residues, in
237 which case cell metabolism would appear as a major regulator of these interactions.
238 This is particularly important for PSC function because many RBPs are essential
239 regulators of pluripotency maintenance and exit [35]. For instance, K536 in the YTH
240 domain of YTHDF2, which selectively recognizes the m⁶A modification on RNA
241 [36], was identified as a high-confidence Kcr site. This may affect its binding affinity
242 to m⁶A modified RNA and in turn regulate cell fate, as this RNA modification is

243 necessary for pluripotency exit [37]. As for the ribosome, it is known that
244 post-translational modifications of ribosome subunits influence protein translation
245 [38], also suggesting a potential link of this function with cell metabolism. Notably,
246 translational control has been implicated in pluripotency maintenance and
247 differentiation [39, 40]. KEGG analysis showed enrichment in terms related to carbon
248 metabolism and the proteasome (Figure 2F and Table S2A).

249 Because lysine residues are subjected to other posttranslational modifications in
250 addition to crotonylation, we also compared our Kcr sites with reported acetylation,
251 malonylation, succinylation, and ubiquitination mouse datasets from the Protein
252 Lysine Modifications Database (PLMD) [41]. Our high-confidence Kcr sites
253 significantly overlapped with other modifications, but a large number of Kcr sites
254 were unique (Figure S3C and Table S2C). Moreover, we observed that the average
255 amino acid distribution around crotonylated lysines is enriched in glutamic acid (E),
256 in agreement with a previous crotonylome study [15] (Figure S3D). The negative
257 charge of glutamic acid residues might synergize with the crotonylation-mediated
258 suppression of lysine's positive charge, changing the affinity of RBPs for substrates.
259 Interestingly, it was reported that the glutamic acid-lysine (EK) rich region of the
260 splicing factor SREK1/SRrp86 can function as an inhibitor of splicing [42]. Two
261 lysine residues in this same domain of SREK1/SRrp86 were identified as
262 low-confidence candidate sites in our dataset (Figure S3E and S3F).

263 Overall, these results demonstrate that protein crotonylation is a widespread
264 lysine modification in mouse PSCs and early differentiating cells, affecting proteins
265 with relevant functions in pluripotency maintenance and differentiation.

266

267 **Dynamics of protein crotonylation in the four cell states**

268 We next compared the individual crotonylomes of the three pluripotent states and
269 differentiating cells to gain insight into the potential functional consequences of
270 differential protein crotonylation levels. For this purpose, we applied variance

271 analysis (ANOVA with a cut-off of $q < 0.01$) and hierarchical clustering to the
272 respective high-confidence crotonylated peptide datasets. We initially focused on
273 non-histone proteins, which led to the identification of five categories (clusters I to V)
274 among the four cell states (**Figure 3A** and **B**; Table S3A).

275 Cluster I corresponded to proteins highly crotonylated in differentiating cells
276 compared to the three pluripotent states. This category included proteins related to
277 protein translation including RPL7, LIN28A, and PDCD11. Cluster II included
278 proteins displaying the lowest crotonylation level in EpiSCs, and was particularly
279 enriched in proteins related to RNA localization/transport (*e.g.*, NPM1), protein
280 folding (*e.g.*, CCT8), and telomere maintenance (*e.g.*, XRCC5). Regarding the latter,
281 crotonylation has been shown to facilitate telomere maintenance in chemically
282 induced reprogramming [43], suggesting a potential cause-effect link. Cluster III
283 corresponded to proteins that displayed the highest crotonylation level in 2i ESCs
284 compared to the other three cell states, and included proteins related to mRNA
285 processing (*e.g.*, U2AF2) or DNA repair (*e.g.*, KDM1A). Cluster IV consisted of
286 proteins more highly crotonylated in S/L ESCs and differentiating cells compared to
287 2i ESCs and EpiSCs, and included regulators of protein folding (*e.g.*, HSPA8) or
288 tRNA aminoacylation (*e.g.*, SARS). The last category, cluster V, were proteins more
289 highly crotonylated in EpiSCs, and contained cofactors of metabolic processes (*e.g.*,
290 GOT2) and cytoskeletal regulators (*e.g.*, MAP1B). We also observed a significant
291 enrichment of ribonucleoprotein complex related terms in clusters III and IV, albeit to
292 a lesser extent than in cluster II.

293 We looked in more detail into the enrichment of crotonylated peptides belonging
294 to proteins involved in central carbon metabolism-related KEGG terms (TCA cycle,
295 pentose phosphate pathway [PPP], and glycolysis) in the four cell states. The
296 crotonylation levels of these enzymes were highly dynamic among the different cell
297 types (Figure 3C). Notably, we noticed enhanced crotonylation of glycolytic enzymes
298 in EpiSCs compared to naïve ESCs, whereas TCA cycle and PPP enzymes were more

299 enriched in 2i ESCs compared to EpiSCs. These data are consistent with increased
300 glycolytic activity being a major route for energy production in EpiSCs and with the
301 enhanced mitochondrial activity in naive ESCs compared to EpiSCs [6, 7]. This
302 suggests that differential protein crotonylation in these cell states could actually be a
303 contributing cause rather than a consequence of the observed metabolic differences. In
304 this regard, it has been reported that acetylation of metabolic enzymes changes their
305 function as an adaptive mechanism to environmental changes [44, 45].

306 We also observed that many crotonylated peptides were shared between clusters
307 albeit with different intensity in each respective cluster (Figure 3D and E; Table S3B).
308 For instance, the high-confidence K23 and K188 residues of the apoptosis regulator
309 protein SET showed an opposed tendency between 2i ESCs and S/L ESCs, with K23
310 more crotonylated in 2i ESCs and K188 less (Figure S4A and S4B). This suggests: a)
311 that crotonylation of different lysine residues of the same protein could have diverse
312 functional consequences depending on the cell state, and b) that differential
313 crotonylation of the same lysine in different cell states may be involved in causing
314 distinctive functional features.

315 Because protein levels vary among the four cell states, we also performed the
316 differential crotonylation analysis after calibrating the crotonylation level by protein
317 abundance. Proteins with stable expression but that experience changes in their
318 crotonylation status might be more critically involved in determining shifts in cell
319 identity between the four cell states. After normalization, we identified 485
320 differential sites in 330 proteins between the four cell states (Figure S4C and S4D;
321 Table S3C). These sites and proteins distributed in five clusters. Cluster I included
322 proteins highly crotonylated in differentiating cells and was enriched in proteins
323 related to the TCA cycle. Among these, we noticed for example ACLY, which
324 participates in fatty acid synthesis to regulate pluripotency [46]. Cluster II consisted
325 of proteins highly crotonylated in 2i PSCs and was enriched in GO terms related to
326 mRNA processing, ribonucleoprotein complex assembly, and chromatin remodelling.

327 The former GO terms included the classical RBP HNRNPU [47] and the
328 deacetylase/deacetylase HDAC1[48], which has been reported to regulate
329 pluripotency. Cluster III represented proteins highly crotonylated in EpiSCs and
330 contained proteins involved into RNA splicing and transport (*e.g.*, DHX9). Cluster IV
331 represented proteins displaying lower crotonylation in EpiSCs and it was only
332 enriched for proteins related to protein folding (*e.g.*, HSPA9). Cluster V contained
333 proteins more crotonylated in EpiSCs compared to the other cell states. This cluster
334 had higher crotonylation in EpiSCs than Cluster III; however, there were no enriched
335 GO terms from these 20 proteins.

336 Histone crotonylation is highly dynamic during ESCs differentiation and is
337 required for self-renewal [49]. Besides the analysis of non-histone proteins, we
338 identified 25 crotonylation sites in histone proteins (Figure S5 and Table S3D). While
339 extracting the histone for mass spectrometry might increase the number of identified
340 histones crotonylation sites, our dataset is nevertheless valuable for studying the role of
341 histone crotonylation in pluripotency and differentiation.

342 In summary, our data support that dynamic changes in protein crotonylation,
343 which extend beyond the better studied histone targets, likely play relevant roles in
344 controlling the transition between different pluripotent states and pluripotency exit.

345

346 **Crotonic acid enhances pluripotency gene expression associated with increased** 347 **proteasome activity**

348 Given the dynamic changes in protein crotonylation among the four cell states, we
349 next asked whether modulating protein crotonylation would affect PSC pluripotency
350 or differentiation. To test this, we treated S/L ESCs with crotonic acid. We observed
351 significant upregulation of the pluripotency genes *Nanog* and *Dppa2*, and a
352 concomitant downregulation of the differentiation genes *Fgf5* and *Pax6* compared to
353 the control (**Figure 4A**). S/L ESCs treated with crotonic acid that were allowed to
354 gradually differentiate upon LIF withdrawal for four days also exhibited higher

355 pluripotency gene and lower differentiation gene levels than non-treated ESCs (Figure
356 4B), suggesting that enhanced protein crotonylation maintains pluripotency and slows
357 pluripotency exit. It has been reported that crotonic acid treatment in mouse ESCs
358 downregulates a group of pluripotency genes while upregulating two-cell (2C)-like
359 state genes [43]. This state refers to cells closer to early post-fertilization time points,
360 where embryonic cells have totipotent characteristics (can produce trophectoderm and
361 extraembryonic mesoderm rather than only the cell types coming from the three
362 embryonic germ layers). 2C-like cells are known to express lower levels of
363 pluripotency factors than S/L or 2i PSC cultures from which they spontaneously
364 originate [50]. The discrepancy with our data could be due to the use of different cell
365 lines (N33 versus OG2 ESCs) or unnoticed variations in the culture conditions.
366 Considering the very low number (~0.5%) of 2C-like cells in PSC cultures, single-cell
367 gene expression studies would be necessary to fully clarify this. Regardless, the trend
368 of the changes in both studies is in the same direction (increased potency).

369 Then, we sought to understand how crotonylation affects pluripotency. To this
370 end, we first compared the crotonylated proteins in the four states with a reported
371 ESC-specific gene set (genes highly expressed in mouse/human ESCs) [33]. This
372 showed that 466 ESC-specific gene-encoded proteins are crotonylated (Figure S6A).
373 GO cellular component analysis of these proteins showed enrichment in terms related
374 to ‘proteasome complex’ as well as ‘peptidase complex’, among others (Figure S6B
375 and Table S4A). Indeed, most of the proteasome complex subunits were crotonylated
376 (29/34 total and 22/34 high-confidence) in our dataset (Figure 4C and Table S4B). It
377 has been shown that proteasome activity is positively associated with pluripotency
378 maintenance [17, 18], and our crotonylated dataset included the two proteasomal
379 subunits, PSMD11 and PSMD14, reported as pluripotency regulators. Thus, we tested
380 chymotrypsin-like proteasome activity in S/L ESCs treated or untreated with crotonic
381 acid. Adding crotonic acid significantly enhanced proteasome activity compared to
382 the control in crude lysate (Figure 4D) and also in the native gel assay (Figure 4E and

383 4F). The latter experiment can separate active proteasome complexes from other
384 biomacromolecules based on the molecular weight [51]. Moreover, western blotting
385 showed that the increase of protein crotonylation signals caused by adding crotonic
386 acid associate with a decrease of poly-ubiquitin and K48-ubiquitin signals in cell
387 lysates (Figure 4G). This further points to an increase in proteasome activity after
388 crotonic acid treatment.

389 Taken together, these experiments suggested a link between crotonylation of
390 proteasome subunits in PSCs and pluripotency maintenance. Additional work will be
391 necessary to clarify whether this link is causal and how it relates to the crotonylation
392 of other proteins involved in pluripotency control including histones [14].

393

394 **Conclusions**

395 Our global atlas of protein crotonylation in four different pluripotent cell states has
396 identified targets essential for pluripotency regulation. Among these, it is worth
397 noting factors involved in RNA biogenesis, protein translation, metabolic factors, and
398 proteasome subunits. Further work will be important to validate the specific impact of
399 crotonylation on the function of these proteins, and also how these effects crosstalk
400 with the consequences on gene expression of histone crotonylation [49]. Hence, our
401 dataset will be an important resource for future studies on pluripotency and early
402 pluripotency exit. Our results may also be helpful to understand how changes in
403 metabolism influence cell function in other contexts through variation in the levels of
404 crotonyl-CoA.

405

406 **Materials and methods**

407 **Isolation of ESCs and EpiSCs**

408 OG2 ESCs were isolated in previous study [52]. For derivation of OG2 EpiSCs, the
409 late epiblast layer was dissected intact from a pre-gastrulation stage mouse blastocyst
410 [E5.75], maintained in FA medium (DMEM/F12 [Catalog No. SH30023.01B,

411 Hyclone, Buckinghamshire, United Kingdom] and Neurobasal medium [Catalog No.
412 21103049, Gibco, Carlsbad, CA] mixed 1:1, supplemented with 1× non-essential
413 amino acids [Catalog No. 11140050, Gibco], 1× GlutaMAX [Catalog No. 35050061,
414 Gibco], 1 mM sodium pyruvate [Catalog No. 11360070, Gibco], 50 U/ml
415 penicillin/streptomycin [Catalog No. SV30010, Hyclone], 1× N-2 [Catalog No.
416 17502048, Gibco], 1× B-27 [Catalog No. 17504044, Gibco], 12.5 ng/ml bFGF
417 [Catalog No. 233-FB-050, R&D, Minneapolis, MN], and 20 ng/ml Activin A [Catalog
418 No. 338-AC-050, R&D]) on Matrigel (Catalog No. 354248, Corning, Corning,
419 NY)-coated plates and passaged 4-8 days after isolation.

420

421 **ESC and HEK293T culture**

422 OG2 ESCs were cultured in the presence of 1× non-essential amino acids, 1×
423 GlutaMAX, 1 mM sodium pyruvate, 50 U/ml penicillin/streptomycin, 1000 U/ml LIF
424 (Catalog No. ESG1107, Millipore, Darmstadt, Germany), in either DMEM-high
425 glucose medium (Catalog No. SH30022.01, Hyclone) supplemented with 15% fetal
426 bovine serum (Catalog No. S1580 Biowest, Nuaille, France) on feeder
427 (mitomycin-treated mouse embryonic fibroblasts)-coated plates (for the S/L
428 condition) or DMEM/F12 and Neurobasal medium mixed 1:1, supplemented with 1×
429 N-2, 1× B-27, 1 μM PD0325901, and 3 μM CHIR99021 on 0.1% gelatin (Catalog No.
430 ES-006-B, Millipore)-coated plates (for the 2i condition). For differentiating cells,
431 ESCs were cultured in the same medium as S/L ESCs but without LIF and on 0.1%
432 gelatin-coated plates for four days. HEK293T cells were cultured in DMEM-high
433 glucose supplemented with 10% fetal bovine serum.

434

435 **Protein extraction and trypsin digestion for LC-MS/MS**

436 Cells were lysed on ice in a buffer containing 8 M urea, 10 mM DTT, 50 mM
437 nicotinamide, 3 μM TSA, and 1× protease inhibitor cocktail (Catalog No.
438 11697498001, Roche, Basel, Switzerland). Lysates were centrifuged (20,000 g) at 4

439 °C for 10 minutes. Supernatants were precipitated with cold 15% trichloroacetic acid
440 at -20 °C for 2 hours, following 20,000 g centrifugation at 4 °C for 10 minutes. The
441 precipitated proteins were dissolved in a pH 8.0 buffer containing 8 M urea and 100
442 mM triethylammonium bicarbonate buffer. The protein solution was reduced with 10
443 mM DTT at 37 °C for 1 hour followed by alkylation with 20 mM iodoacetamide at
444 room temperature for 45 minutes protected from light. The alkylated protein samples
445 were diluted by adding 100 mM triethylammonium bicarbonate buffer. Trypsin
446 (Catalog No. V5111, Promega, Madison, WI) was added at 1:50 (w/w) trypsin to
447 protein ratio overnight, and then at 1:100 ratio for 4 hours.

448

449 **TMT labelling**

450 The digested proteins were desalted by running on a Strata X C18 SPE column
451 (Catalog No. 8B-S100-AAK, Phenomenex, Torrance, CA) and then vacuum-dried.
452 Desalted peptides were labelled with TMTsixplex™ Isobaric Label Reagent Set
453 (Catalog No. 90061, ThermoFisher Scientific, Waltham, MA) following the
454 manufacturer's protocol. Briefly, TMT was added at 1:1 (U/mg) TMT reagent to
455 protein ratio for 2 hours at room temperature and then the samples were desalted.

456

457 **Peptide fractionation**

458 TMT-labelled peptides were fractionated by high pH reverse-phase HPLC using an
459 ZORBAX Extend-C18 column (Catalog No. 770450-902, Santa Clara, CA) (5 µm
460 particles, 4.6 mm inner diameter, 250 mm length). Briefly, labelled peptides were
461 separated with a gradient of 2-60% acetonitrile in 10 mM ammonium bicarbonate into
462 80 fractions for 80 minutes. Fractionated peptides were combined into 18 fractions for
463 total proteome analysis or 8 fractions for crotonylome analysis.

464

465 **Kcr enrichment**

466 Kcr-containing peptides were dissolved in pH 8.0 NETN buffer (100 mM NaCl, 1
467 mM EDTA, 50 mM Tris-HCl, and 0.5% NP-40). Dissolved peptides were incubated
468 with antiKcr antibody-coated agarose beads (Catalog No. PTM-503, PTM Biolabs,
469 Hangzhou, China) overnight at 4 °C. Beads were then washed with NETN buffer and
470 bound peptides were eluted with 0.1% trifluoroacetic acid. The resulting peptides
471 were desalted with C18 ZipTips (Catalog No. ZTC18S008, Millipore) before
472 LC-MS/MS analysis.

473

474 **LC-MS/MS analysis**

475 Enriched peptides were dissolved in 0.1% formic acid and loaded onto a home-made
476 reverse-phase analytical column (15 cm length, 75 µm inner diameter). Peptide
477 samples were eluted with a gradient elution system: an increasing gradient of solvent
478 A (0.1% formic acid in 98% acetonitrile) from 7% to 20% over 24 minutes, 20% to
479 35% in 8 minutes and climbing to 80% in 5 minutes then holding at 80% for the last 3
480 minutes, all at a constant flow rate of 300 nl/minute on an EASY-nLC 1000 UPLC
481 system (Catalog No. LC120, ThermoFisher Scientific). The eluted peptide samples
482 were analyzed by a Q Exactive PlusTM hybrid quadrupole-OrbitrapTM mass
483 spectrometer (Catalog No. IQLAAEGAAPFALGMAZR, ThermoFisher Scientific).
484 The electrospray voltage was set to 2.0 kV. The m/z scan range was fixed from 350 to
485 1800 for full scan, and intact peptides were detected at a resolution of 70,000.
486 Peptides were then selected for MS/MS using NCE setting as 30 and the fragments
487 were detected at a resolution of 17,500. Data-dependent acquisition was used for MS
488 data collection.

489

490 **LC-MS/MS data analysis**

491 The resulting TMT data were processed using MaxQuant (v.1.4.1.2) with integrated
492 Andromeda search engine [53]. Tandem mass spectra data were searched against
493 non-redundant mouse protein amino acid sequence from Uniprot databases

494 (<https://www.uniprot.org/>) concatenated with reverse decoy database. Trypsin/P was
495 selected as cleavage enzyme permitting up to two missing cleavages per peptide for
496 total proteome analysis or four missing cleavages per peptide for crotonylome
497 analysis. Mass error was set to 10 ppm for precursor ions and 0.02 Da for fragmented
498 ions. Carbamidomethylation on cysteine was specified as fixed modification,
499 oxidation on methionine, cronylation on lysine, and acetylation on the N-terminal of
500 the protein were specified as variable modifications. FDR threshold for proteins,
501 peptides, and modification sites were set at less than 1%. Minimum peptide length
502 was set at 7. For peptide quantification, TMT6plex was selected. All other parameters
503 in MaxQuant were used default setting.

504

505 **Statistical analysis**

506 All statistical analyses were performed using R (3.5.1). For protein homology
507 analysis, protein sequences in identified human crotonylated proteins datasets [15, 23,
508 27-29] were inputted into ‘blastp’ function in blast+ (2.8.1) with the mouse
509 crotonylated proteins we discovered. Resulting homologous proteins with E value <
510 $1e-10$ were considered as overlapping proteins in the human crotonylated proteins
511 datasets. The ‘upset’ function in R package “UpSetR” (1.4.0) was used to visualize
512 the number of identified crotonylated proteins and intersections of this study with the
513 various human crotonylated protein datasets. Pairwise experimental Pearson
514 correlation matrix was generated using ‘cor’ function in R with the option “use =
515 all.obs”. Correlation matrix was clustered using hierarchical clustering by Euclidean
516 distance and complete linkage method. Cell state variation was defined by performing
517 PCA with ‘prcomp’ function in R. For analysis of the differentially modified sites, we
518 used ANOVA test to generate P values for each high-confidence peptide. The
519 generated P values were corrected by multiple hypotheses with FDR
520 (Benjamini-Hochberg). Pearson correlation results and expression data were
521 visualized using the ‘pheatmap’ function within the R package “pheatmap” (1.0.12).

522

523 **Cellular compartment analysis**

524 Subcellular localization of proteins was analyzed using the COMPARTMENTS
525 database [26] in ‘knowledge’ channel. Only the major compartments in eukaryotic
526 cells (nucleus, cytosol, plasma membrane, cytoskeleton, mitochondrion, endoplasmic
527 reticulum, Golgi apparatus, endosome, lysosome, and peroxisome), with possibility
528 score > 1, were selected.

529

530 **GO and KEGG annotation**

531 GO and KEGG annotations were performed using the R package “clusterProfiler”
532 (3.10.1) [54] with the ‘enrichGO’ and ‘enrichKEGG’ function, respectively.

533

534 **Co-modification analysis**

535 For analysis of crosstalk between crotonylation sites and other lysine modifications,
536 we used the PLMD database [41], which lists 20 types of lysine modifications in
537 multiple species. Co-modified sites were generated by merging our dataset with
538 mouse PLMD dataset.

539

540 **Protein domain analysis**

541 Protein domains of crotonylated proteins were annotated using InterProScan
542 (<http://www.ebi.ac.uk/interpro/>) based on protein sequence alignment method with
543 default settings. Fisher’s exact test and standard FDR control method were used to test
544 the enrichment of the annotated domains from crotonylated proteins against
545 proteome-wide domains.

546

547 **Crotonylation motif analysis**

548 The frequency of amino acids surrounding crotonylated lysine residues was generated
549 using iceLogo [55]. Briefly, high-confidence Kcr-central peptide sequences (6 amino

550 acids upstream and downstream of the modified site) were used as input against the
551 precompiled *mus musculus* protein sequences from Swiss-Prot, the percent difference
552 was set as scoring system with a significance cut-off of $P = 0.05$.

553

554 **Validation of crotonylated proteins by co-immunoprecipitation**

555 HEK293T cells were transfected with plasmids producing FLAG-tagged proteins.
556 After transfection, cells were lysed with TNE lysis buffer (50 mM Tris-HCl pH 7.5,
557 150 mM NaCl, 0.5% NP-40, 1 mM EDTA, 10 mM sodium butyrate, and 1× protease
558 inhibitor cocktail). Lysates were sonicated with a Bioruptor (Catalog No. B01020001
559 Diagenode, Ougrée, Belgium) sonicator (low power, 30 second ON/OFF, 5 cycles),
560 followed by 10,000 g centrifugation at 4 °C for 10 minutes to remove the undissolved
561 particles. Then, they were incubated with pre-washed anti-FLAG M2 magnetic beads
562 (Catalog No. M8823, Sigma, Darmstadt, Germany) at 4 °C overnight with rotation,
563 and eluted by heating at 95 °C for 5 minutes with SDS-PAGE loading buffer. The
564 following primary antibodies were used for immunoblotting: anti-FLAG (Catalog No.
565 F7425, Sigma) and anti-Kcr (Catalog No. PTM-501, PTM Biolabs).

566

567 **Western blotting**

568 Western blotting was performed using standard procedure after lysing cells with a
569 buffer containing 10 mM Tris-HCl pH 7.4, 10 mM EDTA, 50 mM NaCl, 1% Triton
570 X-100, 0.1% SDS, 10 mM N-ethylmaleimide, and 1× protease inhibitor cocktail.
571 Lysates were boiled for 10 minutes to ensure inactivation of deubiquitinase enzymes.
572 Denatured lysates were sonicated with a Bioruptor sonicator (low power, 30 second
573 ON/OFF, 5 cycles), followed by 10,000 g centrifugation at 4 °C for 10 minutes to
574 remove undissolved particles. Lysates were then subjected to immunoblotting with
575 the following primary antibodies: anti-polyubiquitin (Catalog No. 14220, Cayman,
576 Ann Arbor, MI), anti-k48-linkage specific polyubiquitin (Catalog No. 8081S, CST,

577 Danvers, MA), anti-NANOG (Catalog No. A300-397A, Bethyl, Montgomery, MA),
578 and anti- β -ACTIN (Catalog No. A2228, Sigma).

579

580 **Proteasome activity assay**

581 Chymotrypsin-like proteasome activity was measured using a Proteasome Activity
582 Assay Kit (Catalog No. ab107921, Abcam, Cambridge, United Kingdom) following
583 the manufacturer's protocol. In brief, cells with or without crotonic acid treatment
584 were collected in 0.5% NP-40 and homogenized by pipetting up and down a few
585 times. After 10,000 g centrifugation at 4 °C for 10 minutes, the supernatants were
586 incubated with proteasome substrate (Suc-LLVY-AMC) at 37 °C for 20 minutes. The
587 released free AMC (7-amino-3-methylcoumarin) fluorescence was detected on a
588 microplate fluorometer (350 nm excitation, 440 nm emission) after 30 minutes and
589 then 60 minutes at 37 °C. Background signal was corrected by subtracting the
590 30-minute reading from the 60-minute reading and data were then normalized against
591 the control sample.

592

593 **Native gel assay for proteasome activity**

594 Native gel assay for proteasome activity was performed according to the previous
595 publication [17]. Briefly, the cells with or without crotonic acid treatment were
596 collected in proteasome activity assay buffer (50 mM Tris-HCl pH 7.5, 5 mM MgCl₂,
597 5 mM ATP, 1 mM DTT, and 10% glycerol) and lysate by passing 10 times through
598 the syringe with 27-G needled. After 12,000 g centrifugation at 4 °C for 10 minutes,
599 the supernatants were loaded on 3–12% NativePAGE Bis-Tris gel (Catalog No.
600 BN1003BOX, Invitrogen, Carlsbad, CA) in NativePAGE running buffer (Catalog No.
601 BN2001, Invitrogen) containing 5 mM MgCl₂ and 1 mM ATP, and run at 4 °C for
602 150 min at 150 V. The native gel was then incubated with 300 μ M Suc-LLVY-AMC
603 (Catalog No. HY-P1002, MedChemExpress, Monmouth Junction, NJ) diluted in
604 NativePAGE running buffer. Chymotrypsin-like proteasome activity was detected on

605 a FluorChem E system (Catalog No. 92-14860-00, ProteinSimple, San Jose, CA) in
606 UV channel with 460 nm filter. The gel was then incubated with transfer buffer with
607 1% SDS for 10 minutes followed by incubation with transfer buffer for 10 minutes.
608 The denatured gel was then transferred to PVDF membrane and incubated with
609 anti-Proteasome 20S alpha antibody (Catalog No. ab22674, Abcam).

610

611 **Ethical statement**

612 Animal experiments in this study were compliant with all relevant ethical regulations
613 for animal research, and conducted under the approval of the Animal Care and Use
614 committee of the Guangzhou Institutes of Biomedicine and Health under licence
615 number 2007007.

616

617 **Data availability**

618 Mass spectrometry proteomic data have been deposited to the ProteomeXchange
619 Consortium via the PRIDE [56] partner repository with the dataset identifier
620 PXD017121. MS/MS spectrum data of all identified crotonylated peptides have been
621 deposited to the ProteinProspector database. They can be accessed in
622 <http://msviewer.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msviewer> by the
623 following search keys: Replicate 1: zxlfv5pcbb; Replicate 2: g7bxkypz5c; Replicate
624 3: rdqvecoj fj.

625

626 **Authors' contributions**

627 ZC and XB conceived the original idea and YL contributed to it. YL performed most
628 of the experiments, CB performed the LC-MS/MS experiments, JM, JH, and MJ
629 contributed to the experiments, YL performed the bioinformatic analyses with help
630 from CW. MAE contributed to all data analysis. LG isolated the EpiSC cell line under
631 the supervision of JC. XB, ZC, and MAE provided financial support and supervised
632 the project. MAE, XB, and YL wrote the manuscript. CB, CW, and GV helped to

633 revise the manuscript. All authors read and approved the final version of the
634 manuscript.

635

636 **Competing interests**

637 ZC is co-founder and chief executive officer of PTM Bio Inc., and CB is an employee.

638 Other authors declare that they have no competing interests.

639

640 **Acknowledgements**

641 We thank all members of the Laboratory of Integrative Biology for their support. We

642 also thank Xiaofei Zhang, from the Guangzhou Institutes of Biomedicine and Health,

643 for constructive advice on proteomic data analyses. This work was supported by the

644 National Key Research and Development Program of China (2016YFA0100102,

645 2016YFA0100701, and 2018YFA0106903), the Strategic Priority Research Program

646 of the Chinese Academy of Sciences (XDA16030502), the Natural Science

647 Foundation of Guangdong Province (2018B030306042), the Youth Innovation

648 Promotion Association of the Chinese Academy of Sciences (2015294), and an

649 Innovation Team Project grant from the Guangzhou Regenerative Medicine and

650 Health Guangdong Laboratory (2018GZR110103001). Carl Ward is supported by a

651 Zhujiang Talent-Overseas Postdoctoral Funding Grant and a President's International

652 Fellowship Initiative grant from the Chinese Academy of Sciences.

653 **References**

- 654 [1] De Los Angeles A, Ferrari F, Xi R, Fujiwara Y, Benvenisty N, Deng H, et al.
655 Hallmarks of pluripotency. *Nature* 2015;525:469–78.
- 656 [2] Weinberger L, Ayyash M, Novershtern N, Hanna JH. Dynamic stem cell states:
657 naive to primed pluripotency in rodents and humans. *Nat Rev Mol Cell Biol*
658 2016;17:155–69.
- 659 [3] Nichols J, Smith A. Naive and primed pluripotent states. *Cell Stem Cell*
660 2009;4:487–92.
- 661 [4] Hanna J, Markoulaki S, Mitalipova M, Cheng AW, Cassady JP, Staerk J, et al.
662 Metastable pluripotent states in NOD-mouse-derived ESCs. *Cell Stem Cell*
663 2009;4:513–24.
- 664 [5] Marks H, Kalkan T, Menafra R, Denissov S, Jones K, Hofemeister H, et al. The
665 transcriptional and epigenomic foundations of ground state pluripotency. *Cell*
666 2012;149:590–604.
- 667 [6] Sperber H, Mathieu J, Wang Y, Ferreccio A, Hesson J, Xu Z, et al. The
668 metabolome regulates the epigenetic landscape during naive-to-primed human
669 embryonic stem cell transition. *Nat Cell Biol* 2015;17:1523–35.
- 670 [7] Zhou W, Choi M, Margineantu D, Margaretha L, Hesson J, Cavanaugh C, et al.
671 HIF1alpha induced switch from bivalent to exclusively glycolytic metabolism during
672 ESC-to-EpiSC/hESC transition. *EMBO J* 2012;31:2103–16.
- 673 [8] Moussaieff A, Rouleau M, Kitsberg D, Cohen M, Levy G, Barasch D, et al.
674 Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early
675 differentiation of embryonic stem cells. *Cell Metab* 2015;21:392–402.
- 676 [9] Shyh-Chang N, Locasale JW, Lyssiotis CA, Zheng Y, Teo RY, Ratanasirintra-
677 S, et al. Influence of threonine metabolism on S-adenosylmethionine and histone
678 methylation. *Science* 2013;339:222–6.
- 679 [10] Choudhary C, Weinert BT, Nishida Y, Verdin E, Mann M. The growing landscape
680 of lysine acetylation links metabolism and cell signalling. *Nat Rev Mol Cell Biol*
681 2014;15:536–50.
- 682 [11] Sabari BR, Zhang D, Allis CD, Zhao Y. Metabolic regulation of gene expression
683 through histone acylations. *Nat Rev Mol Cell Biol* 2017;18:90–101.
- 684 [12] Xie Z, Zhang D, Chung D, Tang Z, Huang H, Dai L, et al. Metabolic Regulation
685 of Gene Expression by Histone Lysine beta-Hydroxybutyrylation. *Mol Cell*
686 2016;62:194–206.
- 687 [13] Tang H, Han M. Fatty Acids Regulate Germline Sex Determination through
688 ACS-4-Dependent Myristoylation. *Cell* 2017;169:457–69 e13.
- 689 [14] Tan M, Luo H, Lee S, Jin F, Yang JS, Montellier E, et al. Identification of 67
690 histone marks and histone lysine crotonylation as a new type of histone modification.
691 *Cell* 2011;146:1016–28.
- 692 [15] Xu W, Wan J, Zhan J, Li X, He H, Shi Z, et al. Global profiling of crotonylation
693 on non-histone proteins. *Cell Res* 2017;27:946–9.
- 694 [16] Yu H, Bu C, Liu Y, Gong T, Liu X, Liu S, et al. Global crotonylome reveals

- 695 CDYL-regulated RPA1 crotonylation in homologous recombination-mediated DNA
696 repair. *Sci Adv* 2020;6:eaay4697.
- 697 [17] Vilchez D, Boyer L, Morantte I, Lutz M, Merkwirth C, Joyce D, et al. Increased
698 proteasome activity in human embryonic stem cells is regulated by PSMD11. *Nature*
699 2012;489:304–8.
- 700 [18] Buckley SM, Aranda-Orgilles B, Strikoudis A, Apostolou E, Loizou E,
701 Moran-Crusio K, et al. Regulation of pluripotency and cellular reprogramming by the
702 ubiquitin-proteasome system. *Cell Stem Cell* 2012;11:783–98.
- 703 [19] Esteban MA, Wang T, Qin B, Yang J, Qin D, Cai J, et al. Vitamin C enhances the
704 generation of mouse and human induced pluripotent stem cells. *Cell Stem Cell*
705 2010;6:71–9.
- 706 [20] Zhuang Q, Li W, Benda C, Huang Z, Ahmed T, Liu P, et al. NCoR/SMRT
707 co-repressors cooperate with c-MYC to create an epigenetic barrier to somatic cell
708 reprogramming. *Nat Cell Biol* 2018;20:400–12.
- 709 [21] Tsanov KM, Pearson DS, Wu Z, Han A, Triboulet R, Seligson MT, et al. LIN28
710 phosphorylation by MAPK/ERK couples signalling to the post-transcriptional control
711 of pluripotency. *Nat Cell Biol* 2017;19:60–7.
- 712 [22] Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, et al. A Myc network
713 accounts for similarities between embryonic stem and cancer cell transcription
714 programs. *Cell* 2010;143:313–24.
- 715 [23] Wei W, Mao A, Tang B, Zeng Q, Gao S, Liu X, et al. Large-Scale Identification
716 of Protein Crotonylation Reveals Its Role in Multiple Cellular Functions. *J Proteome*
717 *Res* 2017;16:1743–52.
- 718 [24] Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of
719 stem cell genes guides creation of epithelial cancer stem cells. *Cell Stem Cell*
720 2008;2:333–44.
- 721 [25] Wan J, Liu H, Chu J, Zhang H. Functions and mechanisms of lysine
722 crotonylation. *J Cell Mol Med* 2019;23:7163–9.
- 723 [26] Binder JX, Pletscher-Frankild S, Tsafou K, Stolte C, O'Donoghue SI, Schneider
724 R, et al. COMPARTMENTS: unification and visualization of protein subcellular
725 localization evidence. *Database* 2014;2014:bau012.
- 726 [27] Wu Q, Li W, Wang C, Fan P, Cao L, Wu Z, et al. Ultradeep Lysine Crotonylome
727 Reveals the Crotonylation Enhancement on Both Histones and Nonhistone Proteins
728 by SAHA Treatment. *J Proteome Res* 2017;16:3664–71.
- 729 [28] Huang H, Wang DL, Zhao Y. Quantitative Crotonylome Analysis Expands the
730 Roles of p300 in the Regulation of Lysine Crotonylation Pathway. *Proteomics*
731 2018;18:e1700230.
- 732 [29] Chen W, Tang D, Xu Y, Zou Y, Sui W, Dai Y, et al. Comprehensive analysis of
733 lysine crotonylation in proteome of maintenance hemodialysis patients. *Medicine*
734 2018;97:e12035.
- 735 [30] Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, et al. YTHDF2 destabilizes
736 m(6)A-containing RNA through direct recruitment of the CCR4-NOT deadenylase

- 737 complex. *Nat Commun* 2016;7:12626.
- 738 [31] Kwon SC, Yi H, Eichelbaum K, Fohr S, Fischer B, You KT, et al. The
739 RNA-binding protein repertoire of embryonic stem cells. *Nat Struct Mol Biol*
740 2013;20:1122–30.
- 741 [32] He C, Sidoli S, Warneford-Thomson R, Tatomer DC, Wilusz JE, Garcia BA, et al.
742 High-Resolution Mapping of RNA-Binding Regions in the Nuclear Proteome of
743 Embryonic Stem Cells. *Mol Cell* 2016;64:416–30.
- 744 [33] Bao X, Guo X, Yin M, Tariq M, Lai Y, Kanwal S, et al. Capturing the
745 interactome of newly transcribed RNA. *Nat Methods* 2018;15:213–20.
- 746 [34] Castello A, Fischer B, Frese CK, Horos R, Alleaume AM, Foehr S, et al.
747 Comprehensive Identification of RNA-Binding Domains in Human Cells. *Mol Cell*
748 2016;63:696–710.
- 749 [35] Ye J, Blelloch R. Regulation of pluripotency by RNA binding proteins. *Cell Stem*
750 *Cell* 2014;15:271–80.
- 751 [36] Zhu T, Roundtree IA, Wang P, Wang X, Wang L, Sun C, et al. Crystal structure of
752 the YTH domain of YTHDF2 reveals mechanism for recognition of
753 N6-methyladenosine. *Cell Res* 2014;24:1493–6.
- 754 [37] Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol N,
755 Salmon-Divon M, et al. Stem cells. m6A mRNA methylation facilitates resolution of
756 naive pluripotency toward differentiation. *Science* 2015;347:1002–6.
- 757 [38] Simsek D, Tiu GC, Flynn RA, Byeon GW, Leppek K, Xu AF, et al. The
758 Mammalian Ribo-interactome Reveals Ribosome Functional Diversity and
759 Heterogeneity. *Cell* 2017;169:1051–65 e18.
- 760 [39] Bulut-Karslioglu A, Biechele S, Jin H, Macrae TA, Hejna M, Gertsenstein M, et
761 al. Inhibition of mTOR induces a paused pluripotent state. *Nature* 2016;540:119–23.
- 762 [40] Sugiyama H, Takahashi K, Yamamoto T, Iwasaki M, Narita M, Nakamura M, et
763 al. Nat1 promotes translation of specific proteins that induce differentiation of mouse
764 embryonic stem cells. *Proc Natl Acad Sci U S A* 2017;114:340–5.
- 765 [41] Xu H, Zhou J, Lin S, Deng W, Zhang Y, Xue Y. PLMD: An updated data resource
766 of protein lysine modifications. *J Genet Genomics* 2017;44:243–50.
- 767 [42] Li J, Barnard DC, Patton JG. A unique glutamic acid-lysine (EK) domain acts as
768 a splicing inhibitor. *J Biol Chem* 2002;277:39485–92.
- 769 [43] Fu H, Tian CL, Ye X, Sheng X, Wang H, Liu Y, et al. Dynamics of Telomere
770 Rejuvenation during Chemical Induction to Pluripotent Stem Cells. *Stem Cell Reports*
771 2018;11:70–87.
- 772 [44] Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al.
773 Lysine acetylation targets protein complexes and co-regulates major cellular functions.
774 *Science* 2009;325:834–40.
- 775 [45] Wang Q, Zhang Y, Yang C, Xiong H, Lin Y, Yao J, et al. Acetylation of metabolic
776 enzymes coordinates carbon source utilization and metabolic flux. *Science*
777 2010;327:1004–7.
- 778 [46] Wang L, Zhang T, Wang L, Cai Y, Zhong X, He X, et al. Fatty acid synthesis is

779 critical for stem cell pluripotency via promoting mitochondrial fission. *EMBO J*
780 2017;36:1330–47.

781 [47] Vizlin-Hodzic D, Johansson H, Ryme J, Simonsson T, Simonsson S. SAF-A has a
782 role in transcriptional regulation of Oct4 in ES cells through promoter binding. *Cell*
783 *Reprogram* 2011;13:13–27.

784 [48] Kidder BL, Palmer S. HDAC1 regulates pluripotency and lineage specific
785 transcriptional networks in embryonic and trophoblast stem cells. *Nucleic Acids Res*
786 2012;40:2925–39.

787 [49] Wei W, Liu X, Chen J, Gao S, Lu L, Zhang H, et al. Class I histone deacetylases
788 are major histone decrotonylases: evidence for critical and broad function of histone
789 crotonylation in transcription. *Cell Res* 2017;27:898–915.

790 [50] Macfarlan TS, Gifford WD, Driscoll S, Lettieri K, Rowe HM, Bonanomi D, et al.
791 Embryonic stem cell potency fluctuates with endogenous retrovirus activity. *Nature*
792 2012;487:57–63.

793 [51] Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL, et al.
794 Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented
795 early in disease by activating cAMP-PKA signaling. *Nat Med* 2016;22:46–53.

796 [52] Liu J, Han Q, Peng T, Peng M, Wei B, Li D, et al. The oncogene c-Jun impedes
797 somatic cell reprogramming. *Nat Cell Biol* 2015;17:856–67.

798 [53] Cox J, Mann M. MaxQuant enables high peptide identification rates,
799 individualized p.p.b.-range mass accuracies and proteome-wide protein quantification.
800 *Nat Biotechnol* 2008;26:1367–72.

801 [54] Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing
802 biological themes among gene clusters. *OMICS* 2012;16:284–7.

803 [55] Colaert N, Helsens K, Martens L, Vandekerckhove J, Gevaert K. Improved
804 visualization of protein consensus sequences by iceLogo. *Nat Methods* 2009;6:786–7.

805 [56] Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu
806 DJ, et al. The PRIDE database and related tools and resources in 2019: improving
807 support for quantification data. *Nucleic Acids Res* 2019;47:D442–D50.

808

809

810 **Figure legends**

811 **Figure 1 Generation of a high-confidence crotonylome map in three**
812 **pluripotent states and differentiating cells.**

813 **A.** Schematic view showing the culture of cells in four different cell states and the
814 workflow for the crotonylome profiling. **B.** Identification of HDAC1 crotonylation in
815 LC-MS/MS; the MS/MS spectrum at m/z 1174.62 Da matches with the peptide
816 –EVTEEEKTK– being crotonylated K7-crotonyl (68.023 Da). **C.** Hierarchical
817 clustering of the normalized \log_2 intensity for crotonylated peptides of three
818 LC-MS/MS experiments (biological replicates) in the four different cell states,
819 colours in the heatmap indicate the pairwise Pearson correlation between the different
820 samples ($n = 3628$). Epi: EpiSCs; Diff: Differentiating cells. **D.** Left: Principal
821 component analysis of the crotonylome in the four different cell states; the variance
822 was calculated using normalized \log_2 intensity. Right: Euclidean distances of
823 crotonylation profiles between the indicated cell states.

824
825 **Figure 2 Characteristics of the crotonylated proteins identified in three**
826 **pluripotent states and differentiating cells.**

827 **A.** Bar plot indicating the number of crotonylated sites in each high-confidence
828 protein in our crotonylome datasets. **B.** Pie chart indicating the subcellular
829 localization of the high-confidence crotonylated proteins. The localization was
830 annotated using the COMPARTMENTS database in ‘knowledge’ channel. **C.**
831 Comparison of our identified crotonylome data with crotonylome datasets from other
832 published studies using human cells. **D.** Validation of protein crotonylation using
833 ectopically expressed FLAG-tagged proteins in HEK293T cells with or without
834 administration of 10 mM crotonic acid for 24 hours. Cell lysates were
835 immunoprecipitated with anti-FLAG magnetic beads and analyzed by
836 immunoblotting with anti-PAN Kcr antibodies. **E.** GO analysis of the high-confidence
837 crotonylated proteins, the top 6 terms with smallest adjusted P value are shown

838 (Fisher's exact test, Benjamini-Hochberg corrected $P < 0.01$). **F.** KEGG analysis of
839 the high-confidence crotonylated proteins, the top 11 terms with smallest adjusted P
840 value are shown (Fisher's exact test, Benjamini-Hochberg corrected $P < 0.01$).

841

842 **Figure 3 Functional clustering of the crotonylated sites in three pluripotent**
843 **states and differentiating cells.**

844 **A.** Heatmap of crotonylated sites in high-confidence proteins shows distinct patterns
845 in the four cell states ($n = 2306$, ANOVA test, FDR < 0.01). Normalized \log_2 intensity
846 were grouped by hierarchical clustering into five clusters. **B.** GO analysis for all five
847 clusters (Fisher's exact test, Benjamini-Hochberg corrected $P < 0.01$, scaled without
848 centering). **C.** Heatmap of differentially crotonylated enzymes involved in central
849 carbohydrate metabolism (glycolysis, TCA cycle, and PPP pathway) (Fisher's exact
850 test, Benjamini-Hochberg corrected $P < 0.01$). **D.** Box plot indicating the number of
851 crotonylated proteins overlapping between two clusters. Arrows indicate the direction
852 of data processing. **E.** Crotonylation levels of specific lysine sites in the overlapped
853 proteins between different clusters.

854

855 **Figure 4 Crotonic acid promotes pluripotency and enhances proteasome**
856 **activity.**

857 **A.** Relative expression of pluripotency and differentiation genes measured by
858 RT-qPCR in ESCs cultured in S/L with or without 10 mM crotonic acid. Data are
859 presented as the mean \pm S.E.M. ($n = 3$ biological replicates with three technical
860 replicates each, two-tailed unpaired Student's t -test). $*P < 0.05$, n.s.: not
861 significant. **B.** Relative expression of representative pluripotency and differentiation
862 genes measured by RT-qPCR in ESCs cultured in S/L and subjected to differentiation
863 by withdrawing LIF over a time-course of 4 days. Data are presented as the mean \pm
864 S.E.M. ($n = 3$ biological replicates with three technical replicates each, two-tailed
865 unpaired Student's t -test). $*P < 0.05$, $**P < 0.01$, and $***P < 0.001$, n.s.: not

866 significant. **C**, Schematic representation of the proteasome complex and the
867 components identified in our crotonylome. Gray (dashed) ellipse: not detected; blue
868 ellipse: low-confidence; red ellipse: high-confidence. **D**. Chymotrypsin-like
869 proteasome activity measurement in ESCs cultured in S/L with or without 10 mM
870 crotonic acid treatment for 48 hours (n = 4 biological replicates, two-tailed unpaired
871 Student's *t*-test). * $P < 0.05$. **E**. Chymotrypsin-like proteasome activity
872 measurement in pre-purified proteasome by native gel electrophoresis, ESCs were
873 cultured in S/L with or without 10 mM crotonic acid treatment for 48 hours. Samples
874 were resolved by denatured SDS-PAGE and western blotting for analysis the 20S
875 proteasome level and loading control. **F**. Quantified densitometry of the result shown
876 in **E**, data are presented as the mean \pm S.E.M. (n = 4 biological replicates, two-tailed
877 unpaired Student's *t*-test). * $P < 0.05$. **G**. Representative western blotting of lysine
878 crotonylation, poly-ubiquitination, and K-48 ubiquitination in ESCs cultured in S/L
879 and untreated or treated with different concentrations of crotonic acid for 48 hours.
880 ACTIN was the loading control.

881

882 **Table 1 Summary of proteome and crotonylome profiling results.**

883

884 **Supplementary material**

885 **Supplementary Figure S1 Characterization of different cell states. Related to**
886 **Figure 1.**

887 **A.** Representative images showing PSCs cultured in different conditions, bright-field
888 (phase) and green fluorescence for the same fields are shown. Scale bar = 100 μ m. **B.**
889 Relative expression of selected pluripotency and differentiation genes measured by
890 RT-qPCR in the four different cell states. Data are presented as mean \pm S.E.M. (n = 3
891 biological replicates with 3 technical replicates each, two-tailed unpaired Student's
892 *t*-test). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$, n.s.: not significant. *Gapdh* was
893 used as the housekeeping control gene. **C.** Hierarchical clustering of the normalized
894 \log_2 intensity for the total proteome of three different LC-MS/MS experiments
895 (biological replicates) in four different cell states, colours in the heatmap indicate
896 pairwise Pearson correlation between the different datasets (n = 4728). **D.** Normalized
897 \log_2 intensity of 'Core ESC-like gene module' and 'Adult tissue stem module' gene
898 sets from MSigDB in the four different cell states (n = 3 biological replicates,
899 two-tailed unpaired Student's *t*-test). ** $P < 0.01$, and *** $P < 0.001$, n.s.: not
900 significant. **E.** Heatmap showing the protein expression levels of crotonylation
901 regulators in our total proteome analysis. **F.** Western blotting showing the global
902 protein crotonylation levels in the four different cell conditions. **G.** Left: PCA of the
903 total proteome in the four different cell states is shown; the variance was calculated
904 using normalized \log_2 intensity. Right: Euclidean distances of proteome profiles
905 between the indicated cell conditions.

906

907 **Supplementary Figure S2 MS/MS spectrum of identified Kcr peptides of the 15**
908 **western blotting-validated proteins in Figure 2D.**

909

910 **Supplementary Figure S3 Functional characterization of the crotonylome in**
911 **different cell states. Related to Figure 2.**

912 **A.** Protein domain enrichment analysis of the high-confidence crotonylated proteins,
913 the top 10 terms with the smallest adjusted P value are shown (Fisher's exact test,
914 Benjamini-Hochberg corrected $P < 0.01$). **B.** Venn diagrams comparing our
915 crotonylated datasets with published mouse ESCs RBP datasets. **C.** Comparison of
916 the numbers of the overlapped lysine sites between our high-confidence crotonylome
917 and other lysine modification datasets in the PLMD database. Ac: acetylation; ubi:
918 ubiquitination; suc: succinylation; mal: malonylation; glu: glutarylation. **D.** Consensus
919 sequence motif extracted from all high-confidence Kcr sites in our datasets. **E.**
920 Schematic showing lysine crotonylation sites in the EK rich region of
921 SREK1/SRrp86. **F.** MS/MS spectrum of K321cr (left) and K334cr (right) for
922 SREK1/SRrp86.

923

924 **Supplementary Figure S4 Crotonylation of SET protein in different cell states.**

925 *Related to Figure 3.*

926 **A.** Crotonylation levels of two lysine sites of SET protein in the four different cell
927 states. Data are presented as the mean \pm S.E.M. ($n = 3$ biological replicates, two-tailed
928 unpaired Student's t -test). * $P < 0.05$, and *** $P < 0.001$. **B.** Schematic showing the
929 high-confidence Kcr sites of SET. Green circle: higher crotonylation level in S/L
930 ESCs than in 2i ESCs; red circle: higher crotonylation level in EpiSCs than in 2i
931 ESCs. **C.** Heatmap of differential crotonylated sites in the four different cell states
932 after being normalized by protein abundance ($n = 485$, ANOVA test, FDR < 0.01). **D.**
933 GO biological process analysis for the different clusters of proteins in **C** (Fisher's
934 exact test, Benjamini-Hochberg corrected $P < 0.01$).

935

936 **Supplementary Figure S5 Histone crotonylation analysis in different cell states.**

937 *Related to Figure 4.*

938 Diagrams showing the quantitative information of histone Kcr sites in the four cell
939 states of our study. For the isoform-specific histone sites that occurred at the same
940 position, the mean normalized intensity has been used.


941 **Supplementary Figure S6 Enrichment for ESC-specific proteins in our**
942 **crotonylome. *Related to Figure 4.***

943 **A.** Venn diagram comparing our crotonylome datasets with the ‘ESC-specific gene
944 sets’. **B.** GO terms for the 466 overlapping proteins from **(A)** (Fisher’s exact test,
945 Benjamini-Hochberg corrected $P < 0.01$).



Figure 1

bioRxiv preprint doi: <https://doi.org/10.1101/2020.09.21.288167>; this version posted September 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).


A




B



C



D



Supplementary Figure 1

bioRxiv preprint doi: <https://doi.org/10.1101/2020.09.21.288167>; this version posted September 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).






Figure 2

bioRxiv preprint doi: <https://doi.org/10.1101/2020.09.21.288167>; this version posted September 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).



Supplementary Figure 2

bioRxiv preprint doi: <https://doi.org/10.1101/2020.09.21.288167>; this version posted September 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).



Supplementary Figure 3







Figure 3


bioRxiv preprint doi: <https://doi.org/10.1101/2020.09.21.288167>; this version posted September 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Supplementary Figure 4







A



B

